Healthcare & Medical Devices Global On demand · 24-48h

Global Nonalcoholic Steatohepatitis Diagnostic Market Strategic Research Report

Global Nonalcoholic Steatohepatitis Diagnostic Market Strate…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Nonalcoholic Steatohepatitis Diagnostic Market
$1.61B2025
5.5%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Serum Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Others

By Application: Pharma & CRO Industry, Hospitals, Academic Research Institutes, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Echosens, Prometheus Laboratories, GENFIT SA, Siemens Medical Solutions USA, Inc., BioPredictive S.A.S, Quest Diagnostics Incorporated., Meridian Bioscience, Inc., Laboratory Corporation of America Holdings

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 93 pages
Market size 2025
$1.61B
Billion USD
Forecast CAGR
5.5%
2025-2032
Forecast 2032
$2.3B
Projected
영역들
5
Asia Pacific · Latin America · MEA · Europe · North America

개요

Scope of the Report

The global Nonalcoholic Steatohepatitis Diagnostic market size is predicted to grow from US$ 1,610 million in 2025 to US$ 2,325 million in 2032; it is expected to grow at a CAGR of 5.5% from 2026 to 2032.

Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease.

The nonalcoholic steatohepatitis (NASH) diagnostic market is driven by the increasing prevalence of NASH and the growing awareness of the disease among healthcare providers and patients. NASH is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized by liver inflammation and fibrosis, and it poses a significant global health burden. The rise in obesity rates, sedentary lifestyles, and unhealthy dietary habits contribute to the growing prevalence of NASH. Additionally, advancements in diagnostic technologies, such as non-invasive imaging techniques and blood biomarker assays, have improved early detection and accurate diagnosis of NASH. However, the market also faces challenges, including the lack of specific and validated diagnostic biomarkers for NASH, as well as the need for additional research and clinical validation to establish standardized diagnostic criteria. Moreover, the complex pathophysiology of NASH requires a multi-modal approach to diagnosis, making the development of comprehensive and cost-effective diagnostic strategies a challenge. To succeed in this market, companies must invest in research and development to identify reliable diagnostic biomarkers, collaborate with healthcare providers to improve disease awareness and diagnosis rates, and work towards developing integrated diagnostic algorithms to enhance NASH diagnosis and patient management.

This report presents a comprehensive overview of the global Nonalcoholic Steatohepatitis Diagnostic market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Serum Biomarkers
  • Hepatic Fibrosis Biomarkers
  • Oxidative Stress Biomarkers
  • Apoptosis Biomarkers
  • Others

Segment by Application

  • Pharma & CRO Industry
  • Hospitals
  • Academic Research Institutes
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Nonalcoholic Steatohepatitis Diagnostic market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Pharma & CRO Industry, Hospitals, Academic Research Institutes evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Nonalcoholic Steatohepatitis Diagnostic Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.5%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.61B
2025
Forecast
$2.3B
2032
CAGR
5.5%
2025–2032
영역들
5
global
Key companies
EchosensPrometheus LaboratoriesGENFIT SASiemens Medical Solutions USA, Inc.BioPredictive S.A.SQuest Diagnostics Incorporated.Meridian Bioscience, Inc.Laboratory Corporation of America Holdings
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Serum BiomarkersHepatic Fibrosis BiomarkersOxidative Stress BiomarkersApoptosis BiomarkersOthers
By Application
Pharma & CRO IndustryHospitalsAcademic Research InstitutesOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Serum Biomarkers
  • 3.1.3 Hepatic Fibrosis Biomarkers
  • 3.1.4 Oxidative Stress Biomarkers
  • 3.1.5 Apoptosis Biomarkers
  • 3.1.6 Others
  • 3.1.7 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Pharma & CRO Industry
  • 4.1.3 Hospitals
  • 4.1.4 Academic Research Institutes
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Echosens
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Prometheus Laboratories
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 GENFIT SA
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Siemens Medical Solutions USA, Inc.
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 BioPredictive S.A.S
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Quest Diagnostics Incorporated.
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Meridian Bioscience, Inc.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Laboratory Corporation of America Holdings
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Nonalcoholic Steatohepatitis Diagnostic market size?
The global Nonalcoholic Steatohepatitis Diagnostic market is estimated at US$ 1.61 billion in 2025 (base year) and is projected to reach US$ 2.33 billion by 2032.
What growth rate is expected for the Nonalcoholic Steatohepatitis Diagnostic market through 2032?
The market is expected to grow at a CAGR of 5.5% from 2026 to 2032, expanding from US$ 1.61 billion in 2025 to US$ 2.33 billion in 2032, roughly 1.4 times its base-year value.
How is Nonalcoholic Steatohepatitis Diagnostic defined?
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease.
How is the Nonalcoholic Steatohepatitis Diagnostic market segmented by type?
By type, the market is segmented into Serum Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers and Others.
What are the key applications of Nonalcoholic Steatohepatitis Diagnostic?
Key applications covered include Pharma & CRO Industry, Hospitals, Academic Research Institutes and Others.
Which companies are profiled in the Nonalcoholic Steatohepatitis Diagnostic market report?
Key players profiled include Echosens, Prometheus Laboratories, GENFIT SA, Siemens Medical Solutions USA, BioPredictive S.A.S, Quest Diagnostics Incorporated., Meridian Bioscience and Laboratory Corporation of America Holdings.
What geographies does the Nonalcoholic Steatohepatitis Diagnostic market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Nonalcoholic Steatohepatitis Diagnostic?
The nonalcoholic steatohepatitis (NASH) diagnostic market is driven by the increasing prevalence of NASH and the growing awareness of the disease among healthcare providers and patients.
What are the main risks and barriers in the Nonalcoholic Steatohepatitis Diagnostic market?
However, the market also faces challenges, including the lack of specific and validated diagnostic biomarkers for NASH, as well as the need for additional research and clinical validation to establish standardized diagnostic criteria.
Who should buy the Nonalcoholic Steatohepatitis Diagnostic market report?
The report is intended for manufacturers and solution providers, distributors and end users in Pharma & CRO Industry, Hospitals and Academic Research Institutes, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Nonalcoholic Steatohepatitis Diagnostic market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.